The 10-second takeaway
For the quarter ended June 30 (Q2), RTI Biologics beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded and GAAP earnings per share dropped.
Gross margins improved, operating margins increased, net margins contracted.
RTI Biologics reported revenue of $45.2 million. The seven analysts polled by S&P Capital IQ anticipated a top line of $44.2 million on the same basis. GAAP reported sales were 3.9% higher than the prior-year quarter's $43.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.05. The seven earnings estimates compiled by S&P Capital IQ predicted $0.04 per share. GAAP EPS of $0.02 for Q2 were 50% lower than the prior-year quarter's $0.04 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 47.9%, 260 basis points better than the prior-year quarter. Operating margin was 8.9%, 190 basis points better than the prior-year quarter. Net margin was 2.9%, 170 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $43.8 million. On the bottom line, the average EPS estimate is $0.04.
Next year's average estimate for revenue is $177.9 million. The average EPS estimate is $0.16.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 211 members out of 221 rating the stock outperform, and 10 members rating it underperform. Among 47 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 46 give RTI Biologics a green thumbs-up, and one gives it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on RTI Biologics is outperform, with an average price target of $4.78.
Over the decades, small-cap stocks, like RTI Biologics have provided market-beating returns, provided they're value priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add RTI Biologics to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.